Iovance to host roundtable with KOL to discuss melanoma treatments

Iovance Biotherapeutics will host an investor conference call and webcast to discuss lifileucel TIL therapy and the emerging melanoma treatment landscape on June 26, 2023, at 5:00 p.m. ET. During the one-hour event, the Iovance leadership team will provide a brief recap of the C-144-01 trial and clinical data, defined regulatory pathway, and pre-commercial activities for lifileucel in advanced post-anti-PD-1 melanoma. A multidisciplinary panel of key opinion leaders, KOLs, will discuss the disease burden and unmet needs for advanced melanoma patients within current treatment practices, perspectives on TIL therapy and the emerging landscape, and preparations for broad adoption of lifileucel and cell therapies within their treatment centers.